文献速递胸部肿瘤

白细胞介素-15超级激动剂使自然杀伤细胞对所有分子变异型小细胞肺癌具有抗肿瘤疗效

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC.
PubMed 文献 · J Thorac Oncol · 2022-11-21

小细胞肺癌(SCLC)5年生存率低于6%,免疫检查点阻断疗效有限,与T细胞浸润差及MHC-I类分子低表达有关。本研究在涵盖全部分子亚型的SCLC临床前模型中,评估N-803激活的自然杀伤(NK)细胞对SCLC的裂解作用及体内抗肿瘤活性,发现N-803激活的NK细胞可有效裂解所有变异亚型SCLC细胞, regardless of MHC-I类分子表达。

要点

  • N-803激活的NK细胞在体外可有效裂解所有变异亚型SCLC肿瘤细胞
  • 裂解作用不依赖于SCLC细胞的MHC-I类分子表达
  • N-803在SCLC异种移植模型中显示体内抗肿瘤活性

核心结论

  • N-803激活的NK细胞在体外和体内均显示对SCLC的抗肿瘤活性,作者假设N-803可能使多数SCLC患者获益,包括免疫冷肿瘤且缺乏MHC表达者。

研究设计与样本

  • 临床前研究,采用涵盖全部分子亚型的SCLC模型评估NK介导的裂解,包括N-803激活的NK细胞,并用SCLC异种移植模型评估N-803体内抗肿瘤活性。

主要发现

  • 体外和体内数据显示SCLC各亚型对NK细胞裂解的敏感性存在差异。
  • N-803激活的NK细胞可有效裂解所有变异亚型SCLC肿瘤细胞,无论其MHC-I类分子表达如何。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: SCLC is a highly aggressive tumor with a 5-year survival rate of less than 6%. A heterogeneous disease, SCLC is classified into four subtypes that include tumors with neuroendocrine and non-neuroendocrine features. Immune checkpoint blockade has been recently added for the frontline treatment of SCLC; however, this therapy has only led to modest clinical improvements. The lack of clinical benefit in a cancer type known to have a high tumor mutational burden has been attributed to poor T-cell infiltration and low expression of MHC-class I in most SCLC tumors. In an attempt to devise a more effective immunotherapeutic regimen, this study investigated an alternate approach on the basis of the use of the clinical-stage interleukin-15 superagonist, N-803. METHODS: Preclinical models of SCLC spanning all molecular subtypes were used to evaluate the susceptibility of SCLC to natural killer (NK)-mediated lysis in vitro, including NK cells activated by N-803. Antitumor activity of N-803 was evaluated in vivo with a xenograft model of SCLC. RESULTS: In vitro and in vivo data revealed differences in susceptibility of SCLC subtypes to lysis by NK cells and that NK cells activated by N-803 effectively lyse SCLC tumor cells across all variant subtypes, regardless of their expression of MHC-class I. CONCLUSIONS: These findings highlight the potential of a novel immune-based intervention using a cytokine-based therapeutic option for the treatment of SCLC. We hypothesize that N-803 may provide benefit to most patients with SCLC, including those with immunologically cold tumors lacking MHC expression.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Fousek K, Horn LA, Qin H, et al. An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC. J Thorac Oncol. 2022. PMID: 36410696. doi:10.1016/j.jtho.2022.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。